Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
MDM2 E3 ubiquitin ligase
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "MDM2 E3 ubiquitin ligase" in MCE Product Catalog:
3
3 Cited Publications
Research Areas:
A1874 is an orally active BRD4 PROTAC degrader with a DC50 of 32 nM. A1874 degrades BRD4 via the ubiquitin-proteasome system by recruiting the MDM2 E3 ligase, while disrupting the MDM2-p53 interaction to stabilize p53 and upregulate p21, thereby inducing cell cycle arrest and apoptosis. A1874 exhibits selectivity for wild-type p53 cells and MDM2-amplified tumors, and it can be used in research on breast cancer, colorectal cancer, melanoma, lung cancer, lymphoma, myeloid leukemia, osteosarcoma, and glioblastoma .
1
1 Cited Publications
MD-222 is a potent MDM2 PROTAC degrader. MD-222 recruits the CRBN E3 ubiquitin ligase to target and degrade MDM2, and activates the wild-type p53 pathway in cells. MD-222 is used in relevant research on leukemia and breast cancer .
Synonyms: BI 907828
Target:
Research Areas:
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research .
PROTAC PARP1 degrader is a PROTAC PARP1 degrader. PROTAC PARP1 degrader mediates the interaction between PARP1 and MDM2 E3 ubiquitin ligase, thereby inducing ubiquitination of PARP1 and subsequent proteasome-mediated degradation. PROTAC PARP1 degrader selectively inhibits the growth of breast cancer cells. PROTAC PARP1 degrader induces cell apoptosis by activating caspase-3 and phosphatidylserine externalization. PROTAC PARP1 degrader can be used in the research of triple-negative breast cancer .
Cat. No.: HY-159728
Research Areas:
PROTAC PRMT3 degrader 1 is a selective PRMT3 PROTAC degrader with a DC50 of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia .
Cat. No.: HY-114324A
Purity: 98.99%
rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). PROTAC PARP1 degrader is a PROTAC PARP1 degrader. PROTAC PARP1 degrader mediates the interaction between PARP1 and MDM2 E3 ubiquitin ligase, thereby inducing ubiquitination of PARP1 and subsequent proteasome-mediated degradation. PROTAC PARP1 degrader selectively inhibits the growth of breast cancer cells. PROTAC PARP1 degrader induces cell apoptosis by activating caspase-3 and phosphatidylserine externalization. PROTAC PARP1 degrader can be used in the research of triple-negative breast cancer .
Cat. No.: HY-178472
CAS No.: 3106831-75-5
Research Areas:
AurAP14 is an Aurora A PROTAC degrader (DC50 = 120 nM). AurAP14 can form a stable ternary complex with Aurora A kinase and HSP90, recruiting cullin family E3 ubiquitin ligases and MDM2 to mediate the ubiquitination and proteasome degradation of Aurora A kinase. AurAP14 increases p53 levels and decreases C-MYC levels; AurAP14 induces Apoptosis. AurAP14 can be used in the study of non-small cell lung cancer .
Cat. No.: HY-W598456
CAS No.: 1149388-04-4
Target:
Research Areas:
Brigimadlin intermediate-1 is an intermediate of the E3 ubiquitin protein ligase MDM-2 inhibitor Brigimadlin (HY-152859) and can be used to synthesize Antibody-Drug Conjugates (ADCs) .
Cat. No.: HY-P701593
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MDM2; MDM2 Oncogene, E3 ubiquitin Protein ligase; MDM2 Proto-Oncogene; MDM2 P53 Binding Protein Homolog (Mouse); HDM2; P53-Binding Protein; E3 ubiquitin-Protein ligase MDM2; MDM2 Variant FB55; Oncoprotein MDM2; MDM2 Variant FB30; MDM2 Proto-Oncogene, E3 U
Species:
Human
Source:
E. coli
Cat. No.: HY-P701594
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MDM2; MDM2 Oncogene, E3 ubiquitin Protein ligase; MDM2 Proto-Oncogene; MDM2 P53 Binding Protein Homolog (Mouse); HDM2; P53-Binding Protein; E3 ubiquitin-Protein ligase MDM2; MDM2 Variant FB55; Oncoprotein MDM2; MDM2 Variant FB30; MDM2 Proto-Oncogene, E3 U
Species:
Human
Source:
E. coli
Cat. No.: HY-P83705
Synonyms: ACTFS antibody;
Double minute 2 protein antibody;
E3 ubiquitin-protein ligase MDM2 antibody;
Hdm 2 antibody;
Hdm2 antibody;
HDMX antibody;
MDM 2 antibody;
MDM2 antibody;
MDM2 oncogene E3 ubiquitin protein ligase antibody;
MDM2 p53 E3 ubiquitin protein ligase homolog antibody;
MDM2 transformed 3T3 cell double minute 2 p53 binding protein (mouse) binding protein 104kDa antibody;
MDM2_HUMAN antibody;
MDM2BP antibody;
Mouse Double Minute 2 antibody;
MTBP antibody;
Murine Double Minute Chromosome 2 antibody;
Oncoprotein MDM2 antibody;
p53 Binding Protein MDM2 antibody;
p53-binding protein MDM2 antibody;
ubiquitin protein ligase E3 MDM2 antibody;
ubiquitin protein ligase E3 MDM2 antibody
Cat. No.: HY-173369
Research Areas:
PROTAC MAGL degrader-1 is an orally active, moderately blood-brain barrier permeable bifunctional PROTAC (DC50: 60.28 nM) that possesses MAGL degradation activity alongside MDM2 inhibitory activity. PROTAC MAGL degrader-1 recruits E3 ubiquitin ligase MDM2 to mediate ubiquitination of MAGL and subsequent proteasomal degradation. PROTAC MAGL degrader-1 blocks the interaction between MDM2 and P53 and upregulates the expression of tumor suppressor protein P53. PROTAC MAGL degrader-1 is applicable for research on glioblastoma stem cells, melanoma and breast cancer .
Cat. No.: HY-L128
187 compounds
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.
Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).
MCE carefully prepared a unique collection of 187 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
